MiMedx Group Inc. announced the commercial launch of AMNIOFIX Thyroid Shields, a line extension of its AMNIOFIX dehydrated human amnion/chorion membrane allografts intended for use in endocrine surgery after thyroidectomy. The company said the preconfigured sheets are applied to the exposed recurrent laryngeal nerve and parathyroid glands to provide a protective barrier and support healing. MiMedx cited results from a retrospective, single-center study comparing thyroidectomy patients with and without AMNIOFIX applied to fully dissected recurrent laryngeal nerves (n=670 vs n=1,420 matched patients), reporting a lower incidence of recurrent laryngeal nerve damage at 24 hours post-operation in the AMNIOFIX group (3.4%) versus the non-AMNIOFIX group (14.4%; p<0.01). These results have already been presented in the form of a published study, according to the company’s release.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MiMedx Group Inc. published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.